A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel Versus Trastuzumab and Paclitaxel for First-Line Therapy of Metastatic Breast Cancer
This study is testing a new combination of medications to see if adding a chemotherapy drug called Myocet works better than standard treatment for a specific type of advanced breast cancer. Researchers want to find out if this combination can safely and effectively treat cancer that has spread to other parts of the body.
You might be able to join if you have breast cancer that has spread, tests positive for a protein called HER2, and you have not yet received chemotherapy for advanced cancer. You also need to have healthy heart function and measurable tumors.
Participants will be randomly placed into one of two groups to receive either the new three-drug combination or the standard two-drug treatment. Your doctors will closely monitor your health, check your heart function, and track how your tumors respond to the therapy.
The study has locations in places like San Diego, California, Aurora, Colorado, and Coral Springs, Florida, though its current status is listed as unknown so you should check with the study team for availability.
- 1Tests the addition of Myocet to standard breast cancer treatment
- 2For patients with HER2-positive breast cancer that has spread
- 3Requires healthy heart function and no prior chemotherapy for advanced disease
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.